7LD1

Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047

7LD1 の概要

• エントリーDOI: 10.2210/pdb7ld1/pdb
• 関連するPDBエントリー: 7LAA 7LAB 7LCN
• EMDBエントリー: 23279
• 分子名称: Spike glycoprotein, DH1047 heavy chain, DH1047 light chain, ... (6 entities in total)
• 機能のキーワード: rbd antibody, dh1047, sars, covid-19, sars-cov-2 2p s ectodomain, viral protein, immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 9
• 化学式量合計: 533815.24

構造登録者

Manne, K.,Acharya, P. (登録日: 2021-01-12, 公開日: 2021-01-27, 最終更新日: 2024-10-23)

主引用文献

Li, D.,Edwards, R.J.,Manne, K.,Martinez, D.R.,Schafer, A.,Alam, S.M.,Wiehe, K.,Lu, X.,Parks, R.,Sutherland, L.L.,Oguin 3rd, T.H.,McDanal, C.,Perez, L.G.,Mansouri, K.,Gobeil, S.M.C.,Janowska, K.,Stalls, V.,Kopp, M.,Cai, F.,Lee, E.,Foulger, A.,Hernandez, G.E.,Sanzone, A.,Tilahun, K.,Jiang, C.,Tse, L.V.,Bock, K.W.,Minai, M.,Nagata, B.M.,Cronin, K.,Gee-Lai, V.,Deyton, M.,Barr, M.,Von Holle, T.,Macintyre, A.N.,Stover, E.,Feldman, J.,Hauser, B.M.,Caradonna, T.M.,Scobey, T.D.,Rountree, W.,Wang, Y.,Moody, M.A.,Cain, D.W.,DeMarco, C.T.,Denny, T.N.,Woods, C.W.,Petzold, E.W.,Schmidt, A.G.,Teng, I.T.,Zhou, T.,Kwong, P.D.,Mascola, J.R.,Graham, B.S.,Moore, I.N.,Seder, R.,Andersen, H.,Lewis, M.G.,Montefiori, D.C.,Sempowski, G.D.,Baric, R.S.,Acharya, P.,Haynes, B.F.,Saunders, K.O.
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Cell, 184:4203-, 2021

PubMed Abstract: SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques.

PubMed: 34242577
DOI: 10.1016/j.cell.2021.06.021

実験手法

ELECTRON MICROSCOPY (3.4 Å)